We’ve seen it with metrogel; the pharmaceutical companies want to expand the market for their existing successful products by creating followup products.
A Clinical Trial is underway to test Finacea Foam for the papules and pustules of rosacea. Finacea has proved to be a good option for the `acne like’ symptoms of rosacea.
Safety and Efficacy of Azelaic Acid Foam 15% in Papulopustular Rosacea
This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
It is not clear to me how a twice daily foam application of finacea will offer a benefit to those who can already use Finacea cream.
In a market where it costs millions of dollars to get a product officially approved to treat rosacea, it makes sense that derivate Finacea products are brought to the market.
By comparison, Galderma originally manufactured Metrogel 0.75%, and later followed with Metrolotion and Metrocream. Indeed one study found that metrogel, metrolotion, metrocream, noritate, once and twice per day – all the same same
When the patent expired on metrogel 0.75% Galderm turned their sights to a different formulation and increased the active ingredient metronidazole to 1%.
I wouldn’t be surprised to see further Finacea derivative products in the future as Intendis tries to realise the maximum return on their FDA approved products.
No comments yet ↓
There are no comments yet. Be the first by filling out the form below.
Leave a Comment